In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire to buy Roberts in $980mm stock swap

Executive Summary

Shire Pharmaceuticals is buying Roberts Pharmaceuticals (in-licenses drugs) in a $980mm stock swap that values each Roberts common share at about $30.71, a (pr)26% premium to its 10-day pre-announcement trading average. Post merger, Shire shareholders will hold 56% of the new company, and Roberts' will control the rest. The deal is expected to close in the fourth quarter of 1999.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies